Tag: dupilumab

Dupixent (dupilumab)

FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12...

If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis.
CHOP Dupilumab Study

CHOP Receives $2M Philanthropic Gift to Launch Food Allergy Study Using...

"A successful clinical trial would open the possibility of food introduction to more than 3,500 CHOP patients with EoE."
Dupixent (dupilumab)

Dupixent (dupilumab) Study Shows Significant Improvement in Eosinophilic Esophagitis Signs and...

Phase 3 trial in (EoE) to show a significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older
Dupixent

FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...

Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.
dupilumab

FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
AR101+dupilumab

Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...

Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
AR101+dupilumab

Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...

Study scheduled to commence next week.
dupilumab

Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...

"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."
Peanut Allergy Therapy

Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy

More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.